Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johnson Lin

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
Cancer|August 20, 2025
Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study-TCOG T1214 studyHui-Jen Tsai, Ming-Huang Chen, Hsiu-Po Wang, et al.
Therapeutic Advances in Medical Oncology|July 10, 2026
Optimizing third-line and beyond therapies for metastatic colorectal cancer in Taiwan: an evidence-based consensusPei-Hung Chang, Meng-Che Hsieh, Hao-Wei Teng, et al.
Breast Cancer Research and Treatment|September 23, 2021
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimensMing Shen Dai, Yin Hsun Feng, Shang Wen Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2020
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA TrialCristina Saura, Mafalda Oliveira, Yin-Hsun Feng, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
Cancer|August 20, 2025
Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study-TCOG T1214 studyHui-Jen Tsai, Ming-Huang Chen, Hsiu-Po Wang, et al.
Therapeutic Advances in Medical Oncology|July 10, 2026
Optimizing third-line and beyond therapies for metastatic colorectal cancer in Taiwan: an evidence-based consensusPei-Hung Chang, Meng-Che Hsieh, Hao-Wei Teng, et al.
Breast Cancer Research and Treatment|September 23, 2021
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimensMing Shen Dai, Yin Hsun Feng, Shang Wen Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2020
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA TrialCristina Saura, Mafalda Oliveira, Yin-Hsun Feng, et al.
Pageof 10